Short communication (Scientific journals)
Paraneoplastic secretion in parathyroid carcinoma: serum hCG as a tumor marker
VALDES SOCIN, Hernan Gonzalo; BETEA, Daniela; Daly, Adrian et al.
2017In Acta Clinica Belgica, 72 (2), p. 5
Peer Reviewed verified by ORBi
 

Files


Full Text
BIMS-Investigator Award 2017.pdf
Publisher postprint (594.8 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
hCG; paraneoplasia; PTH; vaccine; immunization; survival; creatinine; calcium; serum
Abstract :
[en] Introduction Parathyroid carcinoma (PCa) is a rare presentation of primary hyperparathyroidism (PHPT), accounting for less than 1 % of cases. Differentiating parathyroid cancer from adenoma is clinically challenging. Rubin et al (2008) et al. suggested that urinary hCG might be a marker of disease progression in PCa. In this study, we aimed to investigate whether the hCG+β kit from Roche Diagnostics could distinguish PCa patients from PHPT. Material and methods We studied a series of 8 patients suffering from advanced PCa, referred to the CHU de Liege. A control group of 20 PHPT patients was used as comparative. hCG+β kit on Cobas (Roche Diagnostics) uses 2 monoclonal antibodies that recognize holo-hCG, nicked hCG, β-core fragment and free β-subunit. Limits of hCG detection and quantification are <0.1 and <0.6 mUI/mL. In non pregnant and postmenopausal women and in men, hCG (p95) is <1 (5.3), <7 mUI/mL (8.3) and <2 (2.6) mUI/mL, respectively. Results. The 8 PCa patients (3 women) presented high serum hCG values at: 1.29, 3.46, 5.7, 24.2, 31.2, 34.1, 36.5 and 164 mUI/mL. Values of 1.29 and 3.46 were obtained in 2 postmenopausal women. The lowest value was presented by the only still alive patient. There was a significant correlation (r=0.786; ρ <0.05) between hCG and PTH and a borderline correlation (r=0.750; ρ =0.05) between hCG and calcium concentrations. All PHP patients presented undetectable hCG values. Conclusions These results suggest that serum hCG might have the potential to discriminate between parathyroid adenomas and carcinomas, with a sensibility of 75% (6/8) and a specificity of 100% (0/20). The only patient still alive presented the lowest hCG values. If hCG could be predictive of PCa survival needs to be studied in a larger series of patients.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
VALDES SOCIN, Hernan Gonzalo  ;  Centre Hospitalier Universitaire de Liège - CHU > Service d'endocrinologie clinique
BETEA, Daniela ;  Centre Hospitalier Universitaire de Liège - CHU > Service d'endocrinologie clinique
Daly, Adrian  ;  Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
DELANAYE, Pierre  ;  Centre Hospitalier Universitaire de Liège - CHU > Service de néphrologie
souberbielle, Jean-Claude
BECKERS, Albert ;  Centre Hospitalier Universitaire de Liège - CHU > Service d'endocrinologie clinique
CAVALIER, Etienne  ;  Centre Hospitalier Universitaire de Liège - CHU > Service de chimie clinique
Language :
English
Title :
Paraneoplastic secretion in parathyroid carcinoma: serum hCG as a tumor marker
Alternative titles :
[en] Carcinome parathyroidien et sécrétion paranéoplasique: hCG marqueur tumoral
Publication date :
December 2017
Journal title :
Acta Clinica Belgica
ISSN :
1784-3286
eISSN :
2295-3337
Publisher :
Taylor & Francis
Volume :
72
Issue :
2
Pages :
5
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 18 December 2017

Statistics


Number of views
110 (4 by ULiège)
Number of downloads
85 (2 by ULiège)

Bibliography


Similar publications



Contact ORBi